Menu Close

PERTHERA AT THE ASCO VIRTUAL CONFERENCE 2020

Perthera is proud to be a part of clinical research featured at the 2020 ASCO Virtual Annual Conference. Using the Perthera Precision Oncology Platform, physicians and clinical scientists can advance their clinical research efforts to demonstrate findings that have significant clinical implications for the treatment of cancer patients. We welcome all oncologists or clinical scientists who are interested in applying Precision Oncology to their research efforts or clinical care to contact us for more information.

 

This year’s poster, which focuses on KRAS mutations in patients with Pancreatic Cancer, was published in partnership with physicians from several top-class institutions such as Cedars Sinai, Johns Hopkins and the Cleveland Clinic. The Perthera Precision Oncology Platform was utilized in the study to provide structured, curated clinical outcomes data and ranked, therapeutic recommendations to empower clinical researchers and physicians to make significant strides in the improvement of cancer care.

 

Click here to be linked to the official ASCO Virtual Annual Conference 2020 poster presentation page, or click on the poster below to download a copy of our poster!

ASCO ANNUAL 2020 ABSTRACT #4641

The video below, which features Dr. Andrew Hendifar’s (Cedars Sinai) presentation regarding the clinical study, summarizes some of the key findings.  

PERTHERA PUBLICATION EFFORTS

Perthera is proud to add this study to its expansive compendium of research publications. To view other publications Perthera has contributed to, including our latest breakthrough study published in The Lancet Oncology which demonstrated significantly increased overall survival benefit for pancreatic cancer patients, visit our Publications page.

If you’re a physician interested in applying Precision Oncology within your practice for any solid tumor type, and/or are interested in becoming a part of Perthera’s clinical study initiatives, click here to contact us and we’ll connect you with one of our Precision Oncology Consultants for a conversation!